COEP
Income statement / Annual
Last year (2025), Coeptis Therapeutics Holdings Inc's total revenue was $1.36 M,
and the percentage change from the previous year is not available.
In 2025, Coeptis Therapeutics Holdings Inc's net income was -$11.92 M.
See Coeptis Therapeutics Holdings Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2005
|
FY-2004
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2005 |
12/31/2004 |
| Operating Revenue |
$1.36 M |
$0.00 |
$0.00 |
$0.00 |
$75.00 K |
$30.76 K |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$4.20 M
|
$1.04 M
|
$1.00 M
|
$1.00 M
|
$0.00
|
$964.22 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$2.83 M
|
-$1.04 M
|
-$1.00 M
|
-$1.00 M
|
$75.00 K
|
-$933.46 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
-2.08
|
0
|
0
|
0
|
1
|
-30.35
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$1.28 M
|
$2.33 M
|
$6.67 M
|
$20.89 K
|
$0.00
|
$3.54 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$1.15 M
|
$0.00
|
$0.00
|
$0.00
|
$14.12 M
|
$5.77 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$105.00 K
|
$0.00
|
$0.00
|
$0.00
|
$2.92 K
|
$6.61 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$1.25 M
|
$6.68 M
|
$13.82 M
|
$33.17 M
|
$14.12 M
|
$5.78 M
|
$0.00
|
$0.00
|
$308.31 K
|
$10.08 K
|
| Other Expenses |
$11.70 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$148.19 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$14.23 M
|
$9.02 M
|
$20.49 M
|
$33.19 M
|
$14.12 M
|
$5.93 M
|
$0.00
|
$0.00
|
$308.31 K
|
$10.08 K
|
| Cost And Expenses |
$14.41 M
|
$10.05 M
|
$21.49 M
|
$34.20 M
|
$14.12 M
|
$6.89 M
|
$0.00
|
$0.00
|
$308.31 K
|
$10.08 K
|
| Interest Income |
$116.50 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$642.38 K
|
$396.12 K
|
$107.69 K
|
$218.41 K
|
$187.13 K
|
$148.19 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.22 M
|
$1.04 M
|
$1.00 M
|
$1.00 M
|
$447.41 K
|
$323.43 K
|
$171.86 K
|
$0.00
|
-$36.00 K
|
$2.66 M
|
| EBITDA |
-$11.82 M |
-$9.44 M |
-$20.16 M |
-$36.35 M |
-$12.81 M |
-$8.68 M |
$171.86 K |
-$7.07 K |
-$344.00 K |
$2.65 M |
| EBITDA Ratio |
-8.67
|
0
|
0
|
0
|
-170.86
|
-282.33
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-9.57
|
0
|
0
|
0
|
-187.28
|
-223.06
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$766.31 K
|
-$822.92 K
|
$224.59 K
|
-$3.38 M
|
$596.65 K
|
-$2.29 M
|
-$2.23 K
|
-$7.07 K
|
$0.00
|
$2.66 M
|
| Income Before Tax |
-$12.28 M
|
-$10.88 M
|
-$21.27 M
|
-$37.57 M
|
-$13.45 M
|
-$9.16 M
|
-$2.23 K
|
-$7.07 K
|
$0.00
|
$2.65 M
|
| Income Before Tax Ratio |
-9.01
|
0
|
0
|
0
|
-179.32
|
-297.66
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$36.00 K
|
$0.00
|
| Net Income |
-$11.92 M
|
-$10.88 M
|
-$21.27 M
|
-$37.57 M
|
-$13.45 M
|
-$9.16 M
|
-$2.23 K
|
-$7.07 K
|
-$344.00 K
|
$2.65 M
|
| Net Income Ratio |
-8.74
|
0
|
0
|
0
|
-179.32
|
-297.66
|
0
|
0
|
0
|
0
|
| EPS |
-2.81 |
-5.65 |
-0.83 |
-2.87 |
-13.16 |
-0.45 |
-0.0002 |
-0.0132 |
-184.81 |
1421.16 |
| EPS Diluted |
-2.81 |
-5.65 |
-0.83 |
-2.87 |
-13.16 |
-0.45 |
-0.0002 |
-0.0132 |
-184.81 |
1421.16 |
| Weighted Average Shares Out |
$4.23 M
|
$1.93 M
|
$25.69 M
|
$14.30 M
|
$1.02 M
|
$20.44 M
|
$10.78 M
|
$539.06 K
|
$1.86 K
|
$1.86 K
|
| Weighted Average Shares Out Diluted |
$4.23 M
|
$1.93 M
|
$25.69 M
|
$14.30 M
|
$1.02 M
|
$20.44 M
|
$10.78 M
|
$539.06 K
|
$1.86 K
|
$1.86 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
